Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy
- 3rd Edition - March 16, 2026
- Latest edition
- Editor: Herbert B. Newton
- Language: English
The Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy, Third Edition offers a unique cutting-edge collection of basic science and clinical information… Read more
World Book Day celebration
Where learning shapes lives
Up to 25% off trusted resources that support research, study, and discovery.
Description
Description
The Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy, Third Edition offers a unique cutting-edge collection of basic science and clinical information on brain tumor chemotherapy research. This book represents the most complete, single-volume resource available for information on the subject of brain tumor chemotherapy. Including a multidisciplinary approach, this volume combines recent advances in tumor therapy with molecular biology, molecular therapeutics, immunobiology, and immunotherapy approaches in one compilation. Chapters new to this volume include cutting-edge research on the molecular underpinnings of brain tumors such as glioblastoma and other gliomas, and the targeted molecular therapies to consider for treatment.
Key features
Key features
• Offers an up-to-date review of brain tumor chemotherapy
• Includes separate chapters on all major brain tumor types
• Includes an overview of molecular biology and developmental molecular therapeutics
• Features new materials on molecular approaches to brain metastases, methylation analysis, liquid biopsy, cancer neuroscience, and RNA sequencing
• Includes separate chapters on all major brain tumor types
• Includes an overview of molecular biology and developmental molecular therapeutics
• Features new materials on molecular approaches to brain metastases, methylation analysis, liquid biopsy, cancer neuroscience, and RNA sequencing
Readership
Readership
Neuroscientists, neurobiologists, neuro-oncologists, neurologists, post-doctoral fellows, researchers, graduate students in biological and biomedical sciences
Table of contents
Table of contents
SECTION 1: PHARMACOLOGICAL AND CLINICAL APPLICATIONS
1. Pathology of primary and metastatic brain tumors
2. Clinical Pharmacology of Brain Tumor Chemotherapy
3. Anti-Seizure Drugs and Cancer Therapies: Potential Interactions and Impact on Treatment
4. Preclinical Models for Chemotherapy Development
5. Genomics and Proteomics in Neuro-Oncology
6. Methylation Analysis and Application to Brain Tumors
7. Next Generation Sequencing: Overview and Application to Systemic Cancer and Brain Tumors
8. Liquid Biopsy for Neuro-Oncology
9. Overview of RNA Sequencing and Applications to Neuro-Oncology
10. Chemotherapy Resistance
11. Clinical Trial Design and Implementation in Neuro-Oncology
12. Neuro - Oncology and the Blood - Brain Barrier
SECTION 2: INNOVATIVE CHEMOTHERAPY DELIVERY
13. Intra-Arterial Chemotherapy of brain tumors
14. Blood-Brain Barrier Disruption Chemotherapy
15. Interstitial Chemotherapy and Polymer Drug Delivery
16. Intratumoral Chemotherapy and Convection-Enhanced Delivery
17. Bone Marrow Transplantation Chemotherapy
18. CSF Dissemination of Primary Brain Tumors
19. Gene and Viral Therapy Approaches for Brain Tumors
20. Nanoparticles for CNS Cancer Therapy
SECTION 3: MOLECULAR BIOLOGY AND MOLECULAR THERAPEUTICS
21. An Overview of Molecular Genetics of Brain Tumors
22. Cell-Cycle Regulation
23. Targeting Cell Cycle Proteins in Brain Cancer
24. Cell Death Pathways and Chemotherapy in Brain Tumors
25. Growth Factor Signaling Pathways and Targeted Therapy
26. Targeting the RAS-RAF-MEK-ERK Signaling Pathway in Gliomas
27. PI3-kinase, Akt, mTOR, and Treatment
28. Scatter Factor/HGF and c-Met in Glioblastoma
29. Overview of the NTRK Signaling Pathway and Therapeutic Applications to Brain Tumors
30. Sonic Hedgehog Signaling Pathway: Overview and Treatment Considerations in Brain Tumors
31. IDH Mutations in Brain Tumors: Overview and Treatment Approaches
32. Angiogenesis and Angiogenesis Inhibitors in Brain Tumors
33. Bevacizumab and Brain Tumors
34. HDAC Inhibitors as Antineoplastic Agents in Neuro-Oncology
35. Cancer Neuroscience and Brain Tumors
SECTION 4: CHEMOTHERAPY SPECIFIC TUMORS – ADULTS
36. Chemo of HG Astro’s -- traditional
37. Chemotherapy of High-Grade Astrocytomas: Temozolomide
38. Molecular Therapy of High-Grade Gliomas
39. Chemotherapy of Low-Grade Astrocytomas
40. Chemotherapy of Oligodendrogliomas
41. Chemotherapy for Primary Central Nervous System Lymphoma
42. Chemotherapy for Medulloblastoma in Adults
43. Chemotherapy of Adult Ependymoma
44. Medical Therapies for Glioneuronal Tumors
45. Medical Therapy of Schwannomas
46. Chemotherapy of Pineal Parenchymal Tumors
47. Chemotherapy of Meningiomas
48. Traditional chemotherapy approaches for metastatic brain tumors
49. Molecular approaches Brain Metastasis
SECTION 5: CHEMOTHERAPY SPECIFIC TUMORS - PEDIATRICS
49. Chemo of Pediatric Low-Grade Gliomas
50. Chemotherapy of Pediatric Low-Grade Gliomas
51. Chemotherapy of Pediatric High-Grade Gliomas
52. Chemotherapy for Medulloblastoma—Childhood
53. Chemotherapy of Brainstem Gliomas
54. Germ Cell Tumors
55. Chemotherapy of Ependymoma—Childhood
56. Chemotherapy for CNS Atypical Teratoid/Rhabdoid Tumor
57. Pediatric Choroid Plexus Tumors: Current Management and Future Directions
SECTION 6: IMMUNOTHERAPY FOR BRAIN TUMORS
58. Glioblastoma and the Immune Milieu: Overview and Focus on Immune Checkpoint Blockade
59. Checkpoint Inhibitor and T Cell-Based Immunotherapy for Brain Tumors
60. Overview of Dendritic Cell Vaccines for Brain Tumors
61. Overview of Vaccine Strategies Against Epidermal Growth Factor Receptor in Brain Tumors
62. Overview of CNS Vaccines—Pediatrics
SECTION 7: RESPONSE ASSESSMENT, QUALITY OF LIFE, NEUROPSYCHOLOGY AND NEW FRONTIERS
63. Issues in Response Assessment of Brain Tumor Chemotherapy
64. Pseudo-Progression in Neuro-Oncology: Overview, Pathophysiology, and Interpretation
65. Response Assessment in Neuro-oncology (RANO): An Update
66. Quality of Life in Neuro-Oncology
67. Neuropsychology in Patients with Cancer
68. Artificial Intelligence Applications in Neuro-Oncology
69. Ayurveda and Ashwagandha: Overview of Bioactive Components and Potential Applications to Gliomas
1. Pathology of primary and metastatic brain tumors
2. Clinical Pharmacology of Brain Tumor Chemotherapy
3. Anti-Seizure Drugs and Cancer Therapies: Potential Interactions and Impact on Treatment
4. Preclinical Models for Chemotherapy Development
5. Genomics and Proteomics in Neuro-Oncology
6. Methylation Analysis and Application to Brain Tumors
7. Next Generation Sequencing: Overview and Application to Systemic Cancer and Brain Tumors
8. Liquid Biopsy for Neuro-Oncology
9. Overview of RNA Sequencing and Applications to Neuro-Oncology
10. Chemotherapy Resistance
11. Clinical Trial Design and Implementation in Neuro-Oncology
12. Neuro - Oncology and the Blood - Brain Barrier
SECTION 2: INNOVATIVE CHEMOTHERAPY DELIVERY
13. Intra-Arterial Chemotherapy of brain tumors
14. Blood-Brain Barrier Disruption Chemotherapy
15. Interstitial Chemotherapy and Polymer Drug Delivery
16. Intratumoral Chemotherapy and Convection-Enhanced Delivery
17. Bone Marrow Transplantation Chemotherapy
18. CSF Dissemination of Primary Brain Tumors
19. Gene and Viral Therapy Approaches for Brain Tumors
20. Nanoparticles for CNS Cancer Therapy
SECTION 3: MOLECULAR BIOLOGY AND MOLECULAR THERAPEUTICS
21. An Overview of Molecular Genetics of Brain Tumors
22. Cell-Cycle Regulation
23. Targeting Cell Cycle Proteins in Brain Cancer
24. Cell Death Pathways and Chemotherapy in Brain Tumors
25. Growth Factor Signaling Pathways and Targeted Therapy
26. Targeting the RAS-RAF-MEK-ERK Signaling Pathway in Gliomas
27. PI3-kinase, Akt, mTOR, and Treatment
28. Scatter Factor/HGF and c-Met in Glioblastoma
29. Overview of the NTRK Signaling Pathway and Therapeutic Applications to Brain Tumors
30. Sonic Hedgehog Signaling Pathway: Overview and Treatment Considerations in Brain Tumors
31. IDH Mutations in Brain Tumors: Overview and Treatment Approaches
32. Angiogenesis and Angiogenesis Inhibitors in Brain Tumors
33. Bevacizumab and Brain Tumors
34. HDAC Inhibitors as Antineoplastic Agents in Neuro-Oncology
35. Cancer Neuroscience and Brain Tumors
SECTION 4: CHEMOTHERAPY SPECIFIC TUMORS – ADULTS
36. Chemo of HG Astro’s -- traditional
37. Chemotherapy of High-Grade Astrocytomas: Temozolomide
38. Molecular Therapy of High-Grade Gliomas
39. Chemotherapy of Low-Grade Astrocytomas
40. Chemotherapy of Oligodendrogliomas
41. Chemotherapy for Primary Central Nervous System Lymphoma
42. Chemotherapy for Medulloblastoma in Adults
43. Chemotherapy of Adult Ependymoma
44. Medical Therapies for Glioneuronal Tumors
45. Medical Therapy of Schwannomas
46. Chemotherapy of Pineal Parenchymal Tumors
47. Chemotherapy of Meningiomas
48. Traditional chemotherapy approaches for metastatic brain tumors
49. Molecular approaches Brain Metastasis
SECTION 5: CHEMOTHERAPY SPECIFIC TUMORS - PEDIATRICS
49. Chemo of Pediatric Low-Grade Gliomas
50. Chemotherapy of Pediatric Low-Grade Gliomas
51. Chemotherapy of Pediatric High-Grade Gliomas
52. Chemotherapy for Medulloblastoma—Childhood
53. Chemotherapy of Brainstem Gliomas
54. Germ Cell Tumors
55. Chemotherapy of Ependymoma—Childhood
56. Chemotherapy for CNS Atypical Teratoid/Rhabdoid Tumor
57. Pediatric Choroid Plexus Tumors: Current Management and Future Directions
SECTION 6: IMMUNOTHERAPY FOR BRAIN TUMORS
58. Glioblastoma and the Immune Milieu: Overview and Focus on Immune Checkpoint Blockade
59. Checkpoint Inhibitor and T Cell-Based Immunotherapy for Brain Tumors
60. Overview of Dendritic Cell Vaccines for Brain Tumors
61. Overview of Vaccine Strategies Against Epidermal Growth Factor Receptor in Brain Tumors
62. Overview of CNS Vaccines—Pediatrics
SECTION 7: RESPONSE ASSESSMENT, QUALITY OF LIFE, NEUROPSYCHOLOGY AND NEW FRONTIERS
63. Issues in Response Assessment of Brain Tumor Chemotherapy
64. Pseudo-Progression in Neuro-Oncology: Overview, Pathophysiology, and Interpretation
65. Response Assessment in Neuro-oncology (RANO): An Update
66. Quality of Life in Neuro-Oncology
67. Neuropsychology in Patients with Cancer
68. Artificial Intelligence Applications in Neuro-Oncology
69. Ayurveda and Ashwagandha: Overview of Bioactive Components and Potential Applications to Gliomas
Product details
Product details
- Edition: 3
- Latest edition
- Published: March 16, 2026
- Language: English
About the editor
About the editor
HN
Herbert B. Newton
Herbert B. Newton Dr. Newton is currently the Director of the Neuro-Oncology Center and Brain Tumor Institute at the University Hospitals of Cleveland Medical Center and Seidman Cancer Center. He holds the William B. Risman Endowed Chair for Memory and Cognition. He retired as a Professor of neurology and neurosurgery at the Ohio State University Medical Center and the James Cancer Hospital, and was the holder of the Esther Dardinger Endowed Chair in Neuro-Oncology. He trained in neuro-oncology with Drs. Jerome Posner and William Shapiro at Memorial Sloan Kettering Cancer Center in New York and has been in academic neuro-oncology for over 30 years. He has published more than 230 peer-reviewed articles and book chapters and is the Chief Editor or Co-Editor of 13 textbooks in the field of neurology and neuro-oncology. In addition, he has been listed as a Best Doctor (neurology) and Top Doctor for cancer (neuro-oncology) for the past 23 years .
Affiliations and expertise
Neuro-Oncology Program and Brain Tumor Institute at the University Hospitals Cleveland Medical Center and Seidman Cancer CenterView book on ScienceDirect
View book on ScienceDirect
Read Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy on ScienceDirect